Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

@article{Kerlan2013UseOI,
  title={Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.},
  author={V{\'e}ronique Kerlan and Didier Gouet and Michel Marre and {\'E}ric Renard},
  journal={Annales d'endocrinologie},
  year={2013},
  volume={74 5-6},
  pages={
          487-90
        }
}
Insulin degludec is a new basal insulin analogue with an ultra-long duration of action that provides a flat and stable action profile with a duration of action greater than 42 hours. Two clinical trials comparing insulin degludec and insulin glargine in basal-bolus therapy have recently been published. Both were 52-week, multicentre, randomised (3:1), treat-to-target trials in patients already using insulin. In both type 1 (n=629) and type 2 diabetes (n=1006), insulin degludec was non-inferior… CONTINUE READING
3
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-2 OF 2 CITATIONS

Patient Assessment in Clinical Pharmacy

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 13 REFERENCES

Insulin degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes 4 ndocr

  • S Heller, J Buse, +3 authors L Merker
  • Lancet
  • 2012
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine (abstract). Diabetes 2011;60(Suppl

  • T Heise, U Hoevelmann, +3 authors H. Haahr
  • Diabetes 2011;60(Suppl. 1):LB12. inologie
  • 2013
VIEW 2 EXCERPTS

Hypoglycemia, quality-of-life, and impact on costs

  • C Fidler, TE Christensen, S. Gillard
  • J Med Econ 2011;14:645–55
  • 2011
VIEW 2 EXCERPTS

Insulin degludec has a two - fold longer half - life and a more consistent pharmacokinetic profile than insulin glargine ( abstract )

  • T Heise, U Hoevelmann, +3 authors H Haahr
  • Diabetes
  • 2011

Multihexamer formation is the underlying basis for the ultra - long glucose - lowering effect of insulin degludec ( abstract )

  • P Kurtzhals, T Heise, +3 authors C Granhall
  • Diabetes
  • 2011